Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8555290 | 0.91 | LMNA (0.51) | ALDH1A1KDM4EMAPTL3MBTL1LMNA | |
| SCHEMBL6667435 | 0.90 | KDM4E (0.53) | ALDH1A1KDM4EMAPTL3MBTL1LMNA | |
| SCHEMBL4517151 | 0.88 | ALDH1A1 (0.63) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL4513801 | 0.88 | ALDH1A1 (0.63) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL8872114 | 0.87 | KDM4E (0.66) | ALDH1A1KDM4EL3MBTL1LMNAMEN1 | |
| SCHEMBL7925245 | 0.87 | ALDH1A1 (0.62) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL4521072 | 0.87 | ALDH1A1 (0.62) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL4514426 | 0.87 | ALDH1A1 (0.62) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL205046 | 0.85 | ALDH1A1 (0.60) | ALDH1A1KDM4EMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL9342470 | 0.85 | KDM4E (0.60) | ALDH1A1KDM4ESMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-9063126-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2516440-B1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8524703-B2 | Bridgehead amine ring-fused indoles and indolines | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2516440-A1 | BRIDGEHEAD AMINE RING -FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRY DISORDERS | Abbott Laboratories (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2344505-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011075487-A1 | BRIDGEHEAD AMINE RING -FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRY DISORDERS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7189852-B2 | Preparing renzapride (hydrochloride) on a laboratory or industrial scale by a simplified process of forming the acyl chloride derivative of 2-(methoxy),3-acyamino,5-chlorobenzoic acid by reacting oxalyl or thionyl chloride in a solvent, e.g. dimethylformamide; coupling with 1-diazabicylo(3.3.1)nonane | ALIZYME THERAPEUTICS LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| EP-1664048-A2 | PROCESS FOR THE PREPARATION OF RENZAPRIDE AND INTERMEDIATES THEREOF | Alizyme Therapeutics Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050137225-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | KOHN HAROLD (US) | 2005-06-23 | — | — | US | disclosed |
| US-6875774-B2 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | THE UNIVERSITY OF NORTH CAROLINA (US) | 2005-04-05 | — | — | US | disclosed |
| WO-2005023808-A2 | PROCESS FOR THE PREPARATION OF RENZAPRIDE AND INTERMEDIATES THEREOF | ALIZYME THERAPEUTICS LIMITED (GB) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023808-A2 | PROCESS FOR THE PREPARATION OF RENZAPRIDE AND INTERMEDIATES THEREOF | ALIZYME THERAPEUTICS LIMITED (GB) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004013143-A2 | AZA-BRIDGED BICYCLIC AMINE DERIVATIVES FOR USE AS NOVEL CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20040029911-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | NORTH CAROLINA, UNIVERSITY OF, THE | 2004-02-12 | — | — | US | disclosed |
| EP-0337547-B1 | Spirocyclic compounds incorporating five-membered rings with two heteroatoms | MERCK SHARP & DOHME (GB) | 1994-03-02 | — | — | EP | disclosed |
| EP-0337547-A1 | Spirocyclic compounds incorporating five-membered rings with two heteroatoms | MERCK SHARP & DOHME LTD. (GB) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137225-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | CHRNA5, CHRNG, CHRNA4 | ALDH1A1 1433/4885KDM4E 706/4885MAPT 1737/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | ALDH1A1 1307/4885KDM4E 1720/4885MAPT 1916/4885 |
| US-20040029911-A1 | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | CHRNA5, CHRNG, CHRNA4 | ALDH1A1 1433/4885KDM4E 706/4885MAPT 1737/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | ALDH1A1 1307/4885KDM4E 1720/4885MAPT 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.